Cargando…

E-type prostanoid receptor 4 (EP4) in disease and therapy

The large variety of biological functions governed by prostaglandin (PG) E(2) is mediated by signaling through four distinct E-type prostanoid (EP) receptors. The availability of mouse strains with genetic ablation of each EP receptor subtype and the development of selective EP agonists and antagoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Konya, Viktoria, Marsche, Gunther, Schuligoi, Rufina, Heinemann, Akos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pergamon Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661976/
https://www.ncbi.nlm.nih.gov/pubmed/23523686
http://dx.doi.org/10.1016/j.pharmthera.2013.03.006
_version_ 1782270778494943232
author Konya, Viktoria
Marsche, Gunther
Schuligoi, Rufina
Heinemann, Akos
author_facet Konya, Viktoria
Marsche, Gunther
Schuligoi, Rufina
Heinemann, Akos
author_sort Konya, Viktoria
collection PubMed
description The large variety of biological functions governed by prostaglandin (PG) E(2) is mediated by signaling through four distinct E-type prostanoid (EP) receptors. The availability of mouse strains with genetic ablation of each EP receptor subtype and the development of selective EP agonists and antagonists have tremendously advanced our understanding of PGE(2) as a physiologically and clinically relevant mediator. Moreover, studies using disease models revealed numerous conditions in which distinct EP receptors might be exploited therapeutically. In this context, the EP4 receptor is currently emerging as most versatile and promising among PGE(2) receptors. Anti-inflammatory, anti-thrombotic and vasoprotective effects have been proposed for the EP4 receptor, along with its recently described unfavorable tumor-promoting and pro-angiogenic roles. A possible explanation for the diverse biological functions of EP4 might be the multiple signaling pathways switched on upon EP4 activation. The present review attempts to summarize the EP4 receptor-triggered signaling modules and the possible therapeutic applications of EP4-selective agonists and antagonists.
format Online
Article
Text
id pubmed-3661976
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Pergamon Press
record_format MEDLINE/PubMed
spelling pubmed-36619762013-06-01 E-type prostanoid receptor 4 (EP4) in disease and therapy Konya, Viktoria Marsche, Gunther Schuligoi, Rufina Heinemann, Akos Pharmacol Ther Associate editor: P. Holzer The large variety of biological functions governed by prostaglandin (PG) E(2) is mediated by signaling through four distinct E-type prostanoid (EP) receptors. The availability of mouse strains with genetic ablation of each EP receptor subtype and the development of selective EP agonists and antagonists have tremendously advanced our understanding of PGE(2) as a physiologically and clinically relevant mediator. Moreover, studies using disease models revealed numerous conditions in which distinct EP receptors might be exploited therapeutically. In this context, the EP4 receptor is currently emerging as most versatile and promising among PGE(2) receptors. Anti-inflammatory, anti-thrombotic and vasoprotective effects have been proposed for the EP4 receptor, along with its recently described unfavorable tumor-promoting and pro-angiogenic roles. A possible explanation for the diverse biological functions of EP4 might be the multiple signaling pathways switched on upon EP4 activation. The present review attempts to summarize the EP4 receptor-triggered signaling modules and the possible therapeutic applications of EP4-selective agonists and antagonists. Pergamon Press 2013-06 /pmc/articles/PMC3661976/ /pubmed/23523686 http://dx.doi.org/10.1016/j.pharmthera.2013.03.006 Text en © 2013 Elsevier Inc. https://creativecommons.org/licenses/by/4.0/ Open Access under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) license
spellingShingle Associate editor: P. Holzer
Konya, Viktoria
Marsche, Gunther
Schuligoi, Rufina
Heinemann, Akos
E-type prostanoid receptor 4 (EP4) in disease and therapy
title E-type prostanoid receptor 4 (EP4) in disease and therapy
title_full E-type prostanoid receptor 4 (EP4) in disease and therapy
title_fullStr E-type prostanoid receptor 4 (EP4) in disease and therapy
title_full_unstemmed E-type prostanoid receptor 4 (EP4) in disease and therapy
title_short E-type prostanoid receptor 4 (EP4) in disease and therapy
title_sort e-type prostanoid receptor 4 (ep4) in disease and therapy
topic Associate editor: P. Holzer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661976/
https://www.ncbi.nlm.nih.gov/pubmed/23523686
http://dx.doi.org/10.1016/j.pharmthera.2013.03.006
work_keys_str_mv AT konyaviktoria etypeprostanoidreceptor4ep4indiseaseandtherapy
AT marschegunther etypeprostanoidreceptor4ep4indiseaseandtherapy
AT schuligoirufina etypeprostanoidreceptor4ep4indiseaseandtherapy
AT heinemannakos etypeprostanoidreceptor4ep4indiseaseandtherapy